WO2007135684A3 - Method of treatment of anti-cd4 autoimmunity - Google Patents
Method of treatment of anti-cd4 autoimmunity Download PDFInfo
- Publication number
- WO2007135684A3 WO2007135684A3 PCT/IL2007/000627 IL2007000627W WO2007135684A3 WO 2007135684 A3 WO2007135684 A3 WO 2007135684A3 IL 2007000627 W IL2007000627 W IL 2007000627W WO 2007135684 A3 WO2007135684 A3 WO 2007135684A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell mediated
- amino acids
- stretch
- autoimmunity
- elicit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Disclosed by the present application are peptides or polypeptides comprising a stretch of contiguous amino acids consisting of at least 5 amino acids overlapping with a corresponding stretch in CD4 protein, wherein said stretch of contiguous amino acids is characterized by the ability to elicit a T-cell mediated autoimmune response against CD4+ T-cells in a patient with T-cell mediated autoimmunity or to impart on said peptide or polypeptide the ability to elicit a T-cell mediated autoimmune response against CD4+ T-cells in a patient with T-cell mediated autoimmunity. Also disclosed are various applications of these peptides and polypeptides in therapy and diagnostics.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80212506P | 2006-05-22 | 2006-05-22 | |
| US60/802,125 | 2006-05-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007135684A2 WO2007135684A2 (en) | 2007-11-29 |
| WO2007135684A3 true WO2007135684A3 (en) | 2009-04-23 |
Family
ID=38723699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IL2007/000627 Ceased WO2007135684A2 (en) | 2006-05-22 | 2007-05-24 | Method of treatment of anti-cd4 autoimmunity |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007135684A2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2476436T (en) | 2006-08-11 | 2018-02-23 | Life Sciences Res Partners Vzw | IMMUNOGENIC PEPTIDES AND THEIR USE IN IMMUNE DISORDERS |
| ES2676630T3 (en) | 2008-02-14 | 2018-07-23 | Life Sciences Research Partners Vzw | Immunogenic control of tumors and tumor cells |
| EP2719396B1 (en) | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
| WO2009121690A1 (en) | 2008-03-13 | 2009-10-08 | Biotest Ag | Agent for treating disease |
| ES2610327T3 (en) | 2008-03-13 | 2017-04-27 | Biotest Ag | Dosing regimen of anti-CD4 antibodies for the treatment of autoimmune diseases |
| MX2010010026A (en) | 2008-03-13 | 2011-03-21 | Biotest Ag | Agent for treating disease. |
| WO2010092185A2 (en) * | 2009-02-16 | 2010-08-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Scramblase/cd4 interaction inhibitors for the treatment of lentivirus infections |
| GB0920944D0 (en) * | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| HUE055070T2 (en) * | 2010-11-25 | 2021-10-28 | Imnate Sarl | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination |
| GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| EP3352782B1 (en) | 2015-09-25 | 2021-03-31 | ImCyse SA | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| CN109069605B (en) | 2016-04-19 | 2022-11-29 | 易姆赛斯股份公司 | Novel immunogenic CD1d binding peptides |
-
2007
- 2007-05-24 WO PCT/IL2007/000627 patent/WO2007135684A2/en not_active Ceased
Non-Patent Citations (4)
| Title |
|---|
| ABULAFIA-LAPID ET AL.: "T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients", JOURNAL OF CLINICAL VIROLOGY, 2004, pages 31S, S48 - S54 * |
| ABULAFIA-LAPID ET AL.: "T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients-An extended open trial", VACCINE, vol. 23, 2005, pages 2149 - 2153 * |
| ATLAN ET AL.: "Can AIDS be prevented by T-cell vaccination", IMMUNOLOGY TODAY, vol. 14, no. 5, 1993, pages 200 - 202 * |
| ATLAN ET AL.: "Mechanisms of autoimmunity and AIDS: prospects for therapeutic intervention", RES. IMMUNOLOGY, vol. 145, 1994, pages 165 - 183 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007135684A2 (en) | 2007-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007135684A3 (en) | Method of treatment of anti-cd4 autoimmunity | |
| WO2007146269A3 (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
| ATE542896T1 (en) | PROTEIN HYDROLYZATE ENRICHED WITH DPP-IV INHIBITING PEPTIDES AND USE THEREOF | |
| NZ591612A (en) | Prevention, treatment and diagnosis of p.gingivalis infection with peptides | |
| PH12012502372A1 (en) | Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same | |
| WO2003087768A3 (en) | Targets for therapeutic intervention identified in the mitochondrial proteome | |
| WO2007047829A3 (en) | Novel heterodimeric proteins and uses thereof | |
| EP3412680A3 (en) | Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment | |
| WO2006001023A3 (en) | Chimeric proteins and uses thereof | |
| WO2022272033A8 (en) | Extended-release immune cell engaging proteins and methods of treatment | |
| NZ595387A (en) | Peptides for treatment and diagnosis of autoimmune disease | |
| EP4566622A3 (en) | Dap10/dap12 fusion polypeptides | |
| WO2004009625A3 (en) | PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES | |
| WO2006061101A3 (en) | Drug delivery peptides for crossing blood-brain barrier | |
| ATE474589T1 (en) | ANGIOGENIC PEPTIDES AND THEIR USES | |
| WO2004005317A3 (en) | Thrombin peptide derivative dimers | |
| WO2002070665A3 (en) | Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen | |
| WO2007135268A3 (en) | Use of peptides as active slimming ingredients | |
| WO2003015825A3 (en) | Conjugate | |
| WO2008010096A3 (en) | Method for preparing recombinant mycobacterial polypeptides in yeast and their use in diagnosis of mycobacterial related diseases | |
| NZ597470A (en) | Therapeutic peptides, polypeptides ans nucleic acid sequences | |
| NZ591827A (en) | Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject | |
| NZ335136A (en) | Isolated peptides which complex with hla-cw*16 molecules, and uses thereof | |
| WO2002036628A3 (en) | New multimeric interferon beta polypeptides | |
| EP4414384A3 (en) | A recombinant protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07736367 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07736367 Country of ref document: EP Kind code of ref document: A2 |